Verona Pharma Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Verona Pharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Verona Pharma stock.
View analyst ratings for Verona Pharma or view top-rated stocks.

Wall Street analysts have given Verona Pharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Verona Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Verona Pharma saw a increase in short interest in the month of May. As of May 28th, there was short interest totaling 205,500 shares, an increase of 30.4% from the May 13th total of 157,600 shares. Based on an average trading volume of 71,200 shares, the short-interest ratio is presently 2.9 days. Currently, 0.5% of the company's shares are sold short.
View Verona Pharma's Short Interest.

Verona Pharma is scheduled to release its next quarterly earnings announcement on Friday, August 13th 2021.
View our earnings forecast for Verona Pharma.

Verona Pharma plc (NASDAQ:VRNA) issued its quarterly earnings results on Thursday, October, 29th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.18.
View Verona Pharma's earnings history.

Verona Pharma's stock was trading at $4.84 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, VRNA shares have increased by 46.1% and is now trading at $7.07.
View which stocks have been most impacted by COVID-19.

4 brokerages have issued 1 year price objectives for Verona Pharma's stock. Their forecasts range from $17.00 to $23.00. On average, they anticipate Verona Pharma's share price to reach $18.75 in the next year. This suggests a possible upside of 165.2% from the stock's current price.
View analysts' price targets for Verona Pharma or view top-rated stocks among Wall Street analysts.

Some companies that are related to Verona Pharma include Supernus Pharmaceuticals (SUPN), PureTech Health (PRTC), Aurinia Pharmaceuticals (AUPH), Indivior (INVVY), Constellation Pharmaceuticals (CNST), Heron Therapeutics (HRTX), uniQure (QURE), ADC Therapeutics (ADCT), Prelude Therapeutics (PRLD), Y-mAbs Therapeutics (YMAB), COMPASS Pathways (CMPS), PMV Pharmaceuticals (PMVP), Generation Bio (GBIO), Cytokinetics (CYTK) and Design Therapeutics (DSGN).
View all of VRNA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Verona Pharma investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Trevena (TRVN), Pfizer (PFE), Citius Pharmaceuticals (CTXR), electroCore (ECOR), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV) and Vaxart (VXRT).

(VRNA) raised $61 million in an initial public offering (IPO) on Thursday, April 27th 2017. The company issued 4,500,000 shares at $13.49 per share. Jefferies and Stifel acted as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers.

Verona Pharma trades on the NASDAQ under the ticker symbol "VRNA."

Verona Pharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Polar Capital Holdings Plc (1.73%), Ghost Tree Capital LLC (1.62%), Novo Holdings A S (1.45%), Sphera Funds Management LTD. (1.38%), venBio Partners LLC (0.28%) and Schonfeld Strategic Advisors LLC (0.10%). Company insiders that own Verona Pharma stock include Anders Ullman, David Zaccardelli and Mark W Hahn.
View institutional ownership trends for Verona Pharma.

VRNA stock was sold by a variety of institutional investors in the last quarter, including Novo Holdings A S, Polar Capital Holdings Plc, Sphera Funds Management LTD., DAFNA Capital Management LLC, D.A. Davidson & CO., and venBio Partners LLC. Company insiders that have sold Verona Pharma company stock in the last year include Anders Ullman, David Zaccardelli, and Mark W Hahn.
View insider buying and selling activity for Verona Pharma or view top insider-selling stocks.

VRNA stock was purchased by a variety of institutional investors in the last quarter, including Ghost Tree Capital LLC, Quantitative Systematic Strategies LLC, Forefront Analytics LLC, Wedbush Securities Inc., Personal CFO Solutions LLC, and Schonfeld Strategic Advisors LLC.
View insider buying and selling activity for Verona Pharma or or view top insider-buying stocks.

Shares of VRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VRNA stock can currently be purchased for approximately $7.07.

Verona Pharma has a market capitalization of $409.60 million. The company earns $-65,150,000.00 in net income (profit) each year or ($2.57) on an earnings per share basis.

Verona Pharma employs 25 workers across the globe.

The official website for Verona Pharma is www.veronapharma.com.

Verona Pharma is headquartered at 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE.

Verona Pharma's mailing address is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. The company can be reached via phone at 44-20-3283-4200 or via email at [email protected]